Transgene SA TRGNF
Set alert
At close · Oct 30
- YTD
- -25.50%
- 1 year
- +6.43%
- Open
- 0.80
- Prev close
- 0.745
- Mkt cap
- 207.30M
- Vol
- 1.00K
- Avg vol
- 26
- EPS
- -0.20
- P/E
- 0.00
More statistics
- Low
- 0.80
- High
- 0.80
News
4 months ago seekingalpha.com
Transgene SA (TRGNF) Discusses Progress in Individualized Neoantigen Therapeutic Vaccines and Expansion into Early-Stage NSCLC Transcript
Transgene SA (TRGNF) Discusses Progress in Individualized Neoantigen Therapeutic Vaccines and Expansion into Early-Stage NSCLC Transcript
7 months ago seekingalpha.com
Transgene SA (TRGNF) Q4 2025 Earnings Call Transcript
Transgene SA (TRGNF) Q4 2025 Earnings Call Transcript
11 months ago globenewswire.com
Transgene announces the resume of trading of its shares on Euronext Paris as of the opening of the markets
Strasbourg, France, 27 November 2025, 00:15 a.m. CET – Transgene (Euronext Paris: TNG) had requested the suspension of trading of its shares (ISIN: FR0005175080) on Euronext Paris as from Wednesday,…
11 months ago globenewswire.com
Correction: Transgene Announces the Temporary Suspension of Trading of its Shares on Euronext Paris
Strasbourg, France, November 25, 2025, 7:45 p.m. CET – Transgene (Euronext Paris: TNG) has requested Euronext Paris to suspend trading of its shares (ISIN: FR0005175080) as of Wednesday, November 26,…
11 months ago globenewswire.com
Transgene Announces the Temporary Suspension of Trading of its Shares on Euronext Paris
Strasbourg, France, November 25, 2025, 7:45 p.m. CET – Transgene (Euronext Paris: TNG) has requested Euronext Paris to suspend trading of its shares (ISIN: FR0005175080) as of Wednesday, November 26,…
11 months ago seekingalpha.com
Transgene SA (TRGNF) Discusses TG4050 Phase I Immunological Data in Head and Neck Cancer from SITC Presentation Transcript
Transgene SA (OTC:TRGNF) Discusses TG4050 Phase I Immunological Data in Head and Neck Cancer from SITC Presentation November 14, 2025 10:00 AM EST Company Participants Lucie Larguier - VP & Chief…
1 year ago accessnewswire.com
Transgene and BioInvent's Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors
BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesions Data support further development of BT-001 in solid…
1 year ago globenewswire.com
Transgene and BioInvent's Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors
BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesions Data support further development of BT-001 in solid…
1 year ago accessnewswire.com
Transgene and BioInvent to Present Translational Data and Updated Clinical Results on Armed Oncolytic Virus BT-001, at ESMO 2025
- Updated clinical data on BT-001 in combination with pembrolizumab to be presented in a poster - Tumor shrinkage observed in both injected and non-injected lesions LUND, SE / ACCESS Newswire /…
1 year ago globenewswire.com
Transgene and BioInvent to Present Translational Data and Updated Clinical Results on Armed Oncolytic Virus BT-001, at ESMO 2025
Poster presentation on BT-001 in combination with pembrolizumab has shown tumor shrinkage in both injected and non-injected lesions Strasbourg, France, and Lund, Sweden, October 13, 2025, 8:30 a.m.…
1 year ago seekingalpha.com
Transgene SA (TRGNF) Q2 2025 Earnings Call Transcript
Transgene SA (OTC:TRGNF) Q2 2025 Earnings Call September 16, 2025 12:00 PM EDT Company Participants Lucie Larguier - VP & Chief Financial Officer Alessandro Riva - CEO & Chairman of the Board…
1 year ago accessnewswire.com
Transgene and BioInvent to Present Updated Data on Armed Oncolytic virus BT-001 at ESMO 2025
- Poster presentation of updated data on BT-001 from the Phase 1 part of the ongoing Phase 1/2a study in solid tumors - LUND, SE / ACCESS Newswire / July 28, 2025 / BioInvent International AB…
1 year ago globenewswire.com
Transgene and BioInvent to Present Updated Data on Armed Oncolytic virus BT-001, at ESMO 2025
Poster presentation of updated data on BT-001 from the Phase I part of the ongoing Phase I/IIa study in solid tumors Strasbourg, France, and Lund, Sweden, July 28, 2025, 8:30 a.m. CEST – Transgene…
1 year ago globenewswire.com
Transgene Shares (Euronext Paris: TNG) Eligible for Inclusion in PEA-PME Accounts
Strasbourg (France), February 6, 2025, 5:45 p.m. CET—Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, confirms…
2 years ago accesswire.com
BioInvent and Transgene's Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2a Trial in Solid Tumors that Failed Previous Treatments
LUND, SWEDEN / ACCESSWIRE / September 14, 2024 / BioInvent International (STO:BINV) Preliminary data presented at ESMO 2024 demonstrate BT-001 induces tumor regression in patients who failed previous…
2 years ago globenewswire.com
Transgene and BioInvent's Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments
Preliminary data presented at ESMO 2024 demonstrate that BT-001 induces tumor regression in patients who failed previous anti-PD(L)-1 treatment
2 years ago accesswire.com
BioInvent and Transgene to Present Promising Initial Phase 1/2a Data on Oncolytic Virus, BT-001, at ESMO 2024
LUND, SE / ACCESSWIRE / September 09, 2024 / BioInvent International (STO:BINV) BT-001 monotherapy showed stable disease and injected lesions shrinkage in advanced solid tumor patients. Promising…
2 years ago globenewswire.com
Transgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncolytic Virus, BT-001, at ESMO 2024
BT-001 monotherapy showed stable disease and shrinkage of injected lesions in patients with advanced solid tumors. BT-001 in combination with KEYTRUDA® (pembrolizumab) showed promising efficacy data…
2 years ago globenewswire.com
Transgene and BioInvent to Present Poster on Oncolytic Virus, BT-001, at ESMO 2024
Strasbourg, France, and Lund, Sweden, July 22, 2024, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of…
3 years ago seekingalpha.com
Transgene SA (TRGNF) Q2 2023 Earnings Call Transcript
Transgene SA (OTC:TRGNF) Q2 2023 Earnings Conference Call September 20, 2023 12:00 PM ET Company Participants Lucie Larguier - Head of Investor Relations Alessandro Riva - Chairman and Chief…
-
6 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
Stocks That Hit 52-Week Lows On Tuesday